Heparin-induced thrombocytopenia in critically ill patients

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 1, 2015, Pages 49-60

  Warkentin, Theodore E ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

adrenal hemorrhagic necrosis; disseminated intravascular coagulation; heparin induced thrombocytopenia; shock liver

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CRITICALLY ILL PATIENT; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOCARDITIS; FALSE POSITIVE RESULT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNIZATION; IMMUNOASSAY; INTENSIVE CARE; INTERNATIONAL NORMALIZED RATIO; LIVER NECROSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; SEPTICEMIA; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS; CHEMICALLY INDUCED; CRITICAL ILLNESS;

ANTICOAGULANTS; CRITICAL ILLNESS; HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 84928493151     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1398381     Document Type: Article

References (95)

1. Chong B. H., Pitney W. R., Castaldi P. A. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet: 1982; 2 8310 1246 1249
2. Amiral J., Bridey F., Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost: 1992; 68 1 95 96
3. Greinacher A., Pötzsch B., Amiral J., Dummel V., Eichner A., Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost: 1994; 71 2 247 251
4. Warkentin T. E. Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am: 2010; 24 4 755 775, ix
5. Warkentin T. E. HIT paradigms and paradoxes. J Thromb Haemost: 2011; 9 01 105 117
6. Warkentin T. E., Kelton J. G. A 14-year study of heparin-induced thrombocytopenia. Am J Med: 1996; 101 5 502 507
7. Warkentin T. E., Levine M. N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med: 1995; 332 20 1330 1335
8. Warkentin T. E., Roberts R. S., Hirsh J., Kelton J. G. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med: 2003; 163 20 2518 2524
9. Warkentin T. E. HITlights: a career perspective on heparin-induced thrombocytopenia. Am J Hematol: 2012; 87 01 S92 S99
10. Warkentin T. E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin T. E., Greinacher A., eds. Heparin-Induced Thrombocytopenia, 5th ed. Boca Raton, FL CRC Press: 2013; 24 76
11. Warkentin T. E., Greinacher A., Koster A., Lincoff A. M.; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 (6, Suppl): 340S 380S
12. Linkins L. A., Lee D. H. Frequency of heparin-induced thrombocytopenia. In: Warkentin T. E., Greinacher A., eds. Heparin-Induced Thrombocytopenia, 5th ed. Boca Raton, FL CRC Press: 2013; 110 150
13. Warkentin T. E., Chong B. H., Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost: 1998; 79 1 1 7
14. Warkentin T. E., Greinacher A., Gruel Y., Aster R. H., Chong B. H.; scientific and standardization committee of the international society on thrombosis and haemostasis. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost: 2011; 9 12 2498 2500
15. Lo G. K., Juhl D., Warkentin T. E., Sigouin C. S., Eichler P., Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost: 2006; 4 4 759 765
16. Warkentin T. E., Linkins L. A. Non-necrotizing heparin-induced skin lesions and the 4T's score. J Thromb Haemost: 2010; 8 7 1483 1485
17. Cuker A., Gimotty P. A., Crowther M. A., Warkentin T. E. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood: 2012; 120 20 4160 4167
18. Sheridan D., Carter C., Kelton J. G. A diagnostic test for heparin-induced thrombocytopenia. Blood: 1986; 67 1 27 30
19. Warkentin T. E., Hayward C. PM, Smith C. A., Kelly P. M., Kelton J. G. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med: 1992; 120 3 371 379
20. Greinacher A., Michels I., Kiefel V., Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost: 1991; 66 6 734 736
21. Eichler P., Budde U., Haas S., et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost: 1999; 81 4 625 629
22. Warkentin T. E. How I diagnose and manage HIT. Hematology (Am Soc Hematol Educ Program): 2011; 2011 143 149
23. Warkentin T. E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol: 2003; 121 4 535 555
24. Warkentin T. E., Hayward C. PM, Boshkov L. K., et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood: 1994; 84 11 3691 3699
25. Greinacher A., Warkentin T. E. Acquired non-immune thrombocytopenia. In: Marder V. J., Aird W. C., Bennett J. S., Schulman S., White G. C., eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 6th ed. Philadelphia, PA Lippincott Williams & Wilkins: 2013; 796 804
26. Warkentin T. E., Sheppard J. A., Moore J. C., Cook R. J., Kelton J. G. Studies of the immune response in heparin-induced thrombocytopenia. Blood: 2009; 113 20 4963 4969
27. Warkentin T. E., Kelton J. G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med: 2001; 344 17 1286 1292
28. Greinacher A., Kohlmann T., Strobel U., Sheppard J. A., Warkentin T. E. The temporal profile of the anti-PF4/heparin immune response. Blood: 2009; 113 20 4970 4976
29. Warkentin T. E., Sheppard J. A. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood: 2014; 123 16 2485 2493
30. Warkentin T. E., Kelton J. G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med: 2001; 135 7 502 506
31. Kopolovic I., Warkentin T. E. Progressive thrombocytopenia after cardiac surgery in a 67-year-old man. CMAJ: 2014; 186 12 929 933
32. Warkentin T. E., Makris M., Jay R. M., Kelton J. G. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med: 2008; 121 7 632 636
33. Warkentin T. E., Basciano P. A., Knopman J., Bernstein R. A. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood: 2014; 123 23 3651 3654
34. Jay R. M., Warkentin T. E. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of 'spontaneous' HIT? J Thromb Haemost: 2008; 6 9 1598 1600
35. Krauel K., Weber C., Brandt S., et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood: 2012; 120 16 3345 3352
36. Ketha S., Smithedajkul P., Vella A., Pruthi R., Wysokinski W., McBane R. Adrenal haemorrhage due to heparin-induced thrombocytopenia. Thromb Haemost: 2013; 109 4 669 675
37. Greinacher A., Farner B., Kroll H., Kohlmann T., Warkentin T. E., Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost: 2005; 94 1 132 135
38. Warkentin T. E. Think of HIT. Hematology (Am Soc Hematol Educ Program): 2006; 408 414
39. Hong A. P., Cook D. J., Sigouin C. S., Warkentin T. E. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood: 2003; 101 8 3049 3051
40. Warkentin T. E., Elavathil L. J., Hayward C. PM, Johnston M. A., Russett J. I., Kelton J. G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med: 1997; 127 9 804 812
41. Srinivasan A. F., Rice L., Bartholomew J. R., et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med: 2004; 164 1 66 70
42. Warkentin T. E. Should vitamin K be administered when HIT is diagnosed after administration of coumarin? J Thromb Haemost: 2006; 4 4 894 896
43. Kelton J. G., Warkentin T. E. Heparin-induced thrombocytopenia: a historical perspective. Blood: 2008; 112 7 2607 2616
44. Warkentin T. E., Pai M., Cook R. J. Intraoperative anticoagulation and limb amputations in patients with immune heparin-induced thrombocytopenia who require vascular surgery. J Thromb Haemost: 2012; 10 1 148 150
45. Warkentin T. E., Bernstein R. A. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med: 2003; 348 11 1067 1069
46. Warkentin T. E. Heparin-induced skin lesions. Br J Haematol: 1996; 92 2 494 497
47. Warkentin T. E., Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf: 2009; 8 2 129 144
48. Warkentin T. E., Hirte H. W., Anderson D. R., Wilson W. EC, O'Connell G. J., Lo R. C. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med: 1994; 97 5 489 491
49. Hillis C., Warkentin T. E., Taha K., Eikelboom J. W. Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism. Am J Hematol: 2011; 86 7 603 606
50. Rauova L., Hirsch J. D., Greene T. K., et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood: 2010; 116 23 5021 5031
51. Selleng K., Warkentin T. E., Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med: 2007; 35 4 1165 1176
52. Warkentin T. E. Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin: 2011; 27 4 805 823, v
53. Warkentin T. E., Cuker A. Differential diagnosis of heparin-induced thrombocytopenia and scoring systems. In: Warkentin T. E., Greinacher A., eds. Heparin-Induced Thrombocytopenia, 5th ed. Boca Raton, FL CRC Press: 2013; 77 109
54. Siegal D. M., Cook R. J., Warkentin T. E. Acute hepatic necrosis and ischemic limb necrosis. N Engl J Med: 2012; 367 9 879 881
55. Warkentin T. E. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Expert Opin Drug Saf: 2014; 13 1 25 43
56. Selleng S., Malowsky B., Strobel U., et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost: 2010; 8 1 30 36
57. Selleng S., Selleng K., Wollert H. G., et al. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost: 2008; 6 3 428 435
58. Warkentin T. E., Moore J. C., Vogel S., Sheppard J. A., Warkentin N. I., Eikelboom J. W. The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by true heparin-induced thrombocytopenia. Thromb Haemost: 2012; 107 5 998 1000
59. Warkentin T. E., Sheppard J. A., Horsewood P., Simpson P. J., Moore J. C., Kelton J. G. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood: 2000; 96 5 1703 1708
60. Warkentin T. E., Sheppard J. I., Sun J. CJ, Jung H., Eikelboom J. W. Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. J Thromb Haemost: 2013; 11 2 253 260
61. Trehel-Tursis V., Louvain-Quintard V., Zarrouki Y., Imbert A., Doubine S., Stéphan F. Clinical and biologic features of patients suspected or confirmed to have heparin-induced thrombocytopenia in a cardiothoracic surgical ICU. Chest: 2012; 142 4 837 844
62. Warkentin T. E. Heparin-induced thrombocytopenia in the ICU: a transatlantic perspective. Chest: 2012; 142 4 815 816
63. Selleng S., Selleng K., Friesecke S., et al. Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study. J Thromb Thrombolysis: 2014; (e-pub ahead of print)
64. Lo G. K., Sigouin C. S., Warkentin T. E. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol: 2007; 82 12 1037 1043
65. Warkentin T. E., Sheppard J. I., Moore J. C., Sigouin C. S., Kelton J. G. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost: 2008; 6 8 1304 1312
66. Levine R. L., Hergenroeder G. W., Francis J. L., Miller C. C., Hursting M. J. Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study. J Thromb Thrombolysis: 2010; 30 2 142 148
67. Berry C., Tcherniantchouk O., Ley E. J., et al. Overdiagnosis of heparin-induced thrombocytopenia in surgical ICU patients. J Am Coll Surg: 2011; 213 1 10 17, discussion 17-18
68. Martel N., Lee J., Wells P. S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood: 2005; 106 8 2710 2715
69. Warkentin T. E., Sheppard J. A., Sigouin C. S., Kohlmann T., Eichler P., Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood: 2006; 108 9 2937 2941
70. Warkentin T. E., Davidson B. L., Büller H. R., et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest: 2011; 140 2 366 373
71. Warkentin T. E., Cook R. J., Marder V. J., et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood: 2005; 106 12 3791 3796
72. Warkentin T. E., Sheppard J. A., Moore J. C., Moore K. M., Sigouin C. S., Kelton J. G. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med: 2005; 146 6 341 346
73. Lubenow N., Hinz P., Thomaschewski S., et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood: 2010; 115 9 1797 1803
74. Warkentin T. E., Sheppard J. A., Heels-Ansdell D., et al. Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group. Heparin-induced thrombocytopenia in medical surgical critical illness. Chest: 2013; 144 3 848 858
75. Cook D., Meade M., Guyatt G., et al. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med: 2011; 364 14 1305 1314
76. Pouplard C., May M. A., Iochmann S., et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation: 1999; 99 19 2530 2536
77. Pouplard C., May M. A., Regina S., Marchand M., Fusciardi J., Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol: 2005; 128 6 837 841
78. Douketis J., Cook D. J., Meade M., et al. Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: the DIRECT study. Arch Intern Med: 2008; 168 16 1805 1812
79. Rabbat C. G., Cook D. J., Crowther M. A., et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care: 2005; 20 4 357 363
80. Warkentin T. E. Heparin-induced thrombocytopenia: diagnosis and management. Circulation: 2004; 110 18 e454 e458
81. Linkins L. A., Dans A. L., Moores L. K., et al. American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis. Chest: 2012; 141 (2, Suppl): e495S e530S
82. Hopkins C. K., Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion: 2008; 48 10 2128 2132
83. Refaai M. A., Chuang C., Menegus M., Blumberg N., Francis C. W. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost: 2010; 8 6 1419 1421
84. Greinacher A., Warkentin T. E. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin T. E., Greinacher A., eds. Heparin-Induced Thrombocytopenia, 5th ed. Boca Raton, FL CRC Press: 2013; 315 355
85. Heparin Sodium, Injection, USP. Available at: www.hospira.com/Images/EN-3339-81-92293-1.pdf. Accessed December 16, 2014
86. Linkins L. A., Warkentin T. E. Heparin-induced thrombocytopenia: real-world issues. Semin Thromb Hemost: 2011; 37 6 653 663
87. Smythe M. A., Forsyth L. L., Warkentin T. E., Smith M., Sheppard J. I., Shannon F. Progressive, fatal thrombosis associated with heparin-induced thrombocytopenia following cardiac surgery despite therapeutic anticoagulation with argatroban: potential role for PTT and ACT confounding. J Thorac Cardiovasc Anesth: 2014; (e-pub ahead of print)
88. Smythe M. A., Warkentin T. E., Stephens J. L., Zakalik D., Mattson J. C. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol: 2002; 71 1 50 52
89. Lewis B. E., Wallis D. E., Berkowitz S. D., et al. ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation: 2001; 103 14 1838 1843
90. Lewis B. E., Wallis D. E., Leya F., Hursting M. J., Kelton J. G.; Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med: 2003; 163 15 1849 1856
91. Lubenow N., Warkentin T. E., Greinacher A., et al. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res: 2006; 117 5 507 515
92. Warkentin T. E., Pai M., Sheppard J. I., Schulman S., Spyropoulos A. C., Eikelboom J. W. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost: 2011; 9 12 2389 2396
93. Farner B., Eichler P., Kroll H., Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost: 2001; 85 6 950 957
94. Warkentin T. E. Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol: 2010; 3 5 567 581
95. Schindewolf M., Steindl J., Beyer-Westendorf J., et al. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)-findings from the GerHIT multi-centre registry study. Thromb Res: 2014; 134 1 29 35